Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Small Biopharmas Should Be Wary Of Early Results – US FDA Official

Feb 02 2017

• By Sue Sutter

Arrows miss target

Related Content

Carrots and Stick: Biopharma At The White House

Feb 01 2017

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

Sep 21 2016

CDER Taps Genzyme Exec As Deputy Director For Science Operations

Feb 13 2013

Related Companies

Sanofi

Sanofi Genzyme

Ultragenyx Pharmaceutical Inc.

Sarepta Therapeutics, Inc.

Precigen, Inc.

Vertex Pharmaceuticals Incorporated

Additional Topics

Research & Development Clinical Trials Drug Approval Standards BioPharmaceutical

More from R&D

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window